ArticleCureus2026
Priapism as an Initial Presentation of Sickle Cell Disease: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Priapism is a urological emergency defined as an erection lasting more than four hours unrelated to sexual stimulation. Most cases are ischemic and often related to hematologic disorders, especially sickle cell disease (SCD). About 30 to 40 percent of males with SCD experience priapism, usually starting in adolescence. The pathophysiology is linked to nitric oxide depletion, dysregulation of phosphodiesterase type 5, oxidative stress, and genetic factors. Although common, priapism is often overlooked and undertreated, which can lead to erectile dysfunction and psychological problems. A 21-year-old African American man with no prior medical history presented to Henry Ford St. John Hospital with a painful erection of four days' duration. Laboratory evaluation revealed hemoglobin of 11.5 g/dL (reference range: 13.5-17.5 g/dL) and a positive sickle cell solubility test. Hemoglobin electrophoresis confirmed SCD (HbS 61.9%, HbF 35.9%). Initial interventions, including cavernosal aspiration and phenylephrine injection, were unsuccessful, necessitating distal cavernosal shunt surgery. Hydroxyurea therapy was initiated, and the patient was discharged. Four days later, the patient presented a recurrence of priapism. Symptoms resolved after red blood cell exchange transfusion. He was discharged on hydroxyurea and sildenafil, with multidisciplinary follow-up arranged. This case shows that patients without a prior SCD diagnosis can present with priapism as the first sign, even without typical lab abnormalities. Early recognition and prompt treatment, including urologic procedures, hydroxyurea, and red blood cell exchange transfusion, are important to prevent recurrence and long-term complications. Collaboration among urology, hematology, and mental health specialists is crucial for the care of this patient population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.